Drug intelligence / Profile preview

ME4406

Development stage: Preclinical
Lead developer: Meiji
Modality: Small Molecules
Administration: Oral

Overview

ME4406 is an investigational veterinary product being developed by Meiji Seika Pharma. It is formulated as a feed additive for oral administration, intended to promote animal health. As of early 2024, the asset is in the preclinical stage of development. Specific details regarding its chemical structure, biological target, or precise therapeutic indication within the animal health sector have not been disclosed by the developer. It is categorized within Meiji's veterinary drug pipeline alongside other antibacterial and health-promoting agents for livestock.

Beyond the preview

Go deeper on ME4406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ME4406.

Explore the full profile